8 results about "Insulin dependent diabetes" patented technology

A synthesized gel including an extract selected from the group consisting of Gum Arabic (GA) extract, myrhh (MR) extract, a polymer or monomer selected from the group consisting of NIPAm and acidic monomers; APS initiator; MBA; and insulin. A method of treating insulin dependent diabetes includes administering to a patient in need thereof a therapeutically effective amount of the insulin loaded into the gel.

The application belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating diabetes due to deficiency of vital energy and internal heat, a preparation method, application and medicine of the traditional Chinese medicine composition. The composition comprises the following components in parts by mass: 2-8 parts of Astragalus membranaceus, 1-7 parts of Coptis chinensis, 1-7 parts of Pueraria lobata, 1-6 parts of Anemarrhena asphodeloides, 2-8 parts of Dioscorea opposita, 1-7 parts of Lonicera japonica and 1-6 parts of Cynanchum paniculatum. The application solves the problems of high cost or complex preparation process of the medicine composition for treating diabetes in the prior art, and provides the traditional Chinese medicine composition which can clear heat and benefit vital energy, and can be used for diabetes due to deficiency of vital energy and internal heat and mild, moderate type non-insulin dependent diabetes.

The present invention provides a method of treating insulin-dependent diabetes mellitus in a subject, comprising administering to the subject a therapeutically effective amount of a Janus kinase inhibitor, or a pharmaceutically acceptable salt or ester thereof, or a therapeutically effective amount of intravenous immunoglobulin, or a therapeutically effective amount of a therapeutic agent that destroys B lymphocytes, or a combination thereof. The present invention also provides kits containing the same.

To provide a pharmaceutical composition containing a compound or a salt thereof, or a solvate thereof, which has an action similar to that of a GLP-1 peptide as a GLP-1 receptor agonist, can be noninvasively administered, and has improved activity, metabolic stability and bioavailability. The present invention also provides a method for preventing or treating non-insulin-dependent diabetes mellitus (type 2 diabetes) or obesity using the pharmaceutical composition.SOLUTION: The present invention provides a pharmaceutical composition which contains, as an active ingredient, a compound having a basic skeleton represented by formula (I) in which an indole ring and a pyrazolopyridine skeleton are bonded via a substituent, or a salt thereof, or a solvate thereof, and is used in the prevention or treatment of non-insulin-dependent diabetes mellitus (type 2 diabetes mellitus) or obesity.SELECTED DRAWING: None

A series of pharmaceutical compositions containing polypeptide dual agonist compounds and pharmaceutically acceptable salts thereof, wherein same have dual agonist effects on a human glucagon-like peptide-1 (GLP-1) receptor and a human blood glucose-dependent insulinotropic polypeptide (GIP) receptor, and can be used for treating non-insulin-dependent diabetes, insulin-dependent diabetes, obesity and other related diseases.

The current invention discloses methods for treating diseases characterized by elevated levels of the urokinase plasminogen activator receptor (uPAR) protein D2D3 wherein the disease is one or more of chronic kidney disease, insulin-dependent diabetes, or diabetic neuropathy. In addition, the invention provides methods for restoring pancreatic β-cell number and function in the pancreas of a subject diagnosed with insulin-dependent diabetes wherein the insulin-dependent diabetes is characterized by the presence of detectable levels of D2D3 Specifically, the methods comprise administration of a therapeutically effective amount of an agent that antagonizes or removes D2D3 from the circulation of the subject wherein the agent comprises an anti-D2D3 antibody or antigen binding fragment thereof that specifically binds to a D2D3 protein. Alternatively, the methods comprise removing the D2D3 protein from the circulation of the subject by an extracorporeal procedure.

The present invention relates to a novel long-acting acylated oxyntomodulin analogue having dual GLP-1R / GlucagonR agonism and a pharmaceutical composition for preventing or treating obesity and overweight, or non-insulin dependent diabetes mellitus accompanied by obesity and overweight, comprising the same. The acylated oxyntomodulin analogue of the present invention comprises dual GLP-1 / Glucagon receptor agonism and has a very excellent improved in vivo half-life, and the pharmaceutical composition comprising the same can be used to treat metabolic diseases such as obesity and diabetes.

Methods of improving muscle receptor sensitivity to insulin muscle receptors, reducing death, destruction or rejection of beta islets in patients having insulin dependent diabetes, wherein said method comprising the steps of: a) obtaining a patient in need of immune cell therapy; b) administering to said patient immunomodulatory cells; c) assessing the prevention and transition to diabetes requiring insulin.